Global Sample Preservation Solution Market Landscape 2026: Key Manufacturers and Emerging Trends

An industry analysis of the sample preservation sector, highlighting the technologies, manufacturers, and supply chain dynamics shaping the future of diagnostic sample integrity.

Executive Summary: A Steadily Expanding Market

The sample preservation solution market continues its trajectory of steady growth in 2026, driven by the increasing global demand for molecular diagnostics, infectious disease surveillance, and the expansion of decentralized testing infrastructure. According to the latest industry analysis, the global sample preservation solution market was valued at approximately US$ 815 million in 2025 and is forecast to reach a readjusted size of US$ 1.16 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.2% during the review period. Complementing this broader category, the global virus transport medium (VTM) segment specifically achieved a valuation of US$ 214 million in 2025, with projections indicating a rise to US$ 298 million by 2032 at a CAGR of 4.8%.

This growth is underpinned by several concurrent trends: the rising prevalence of respiratory infectious diseases necessitating robust specimen collection infrastructure, the global expansion of molecular diagnostic testing, the increasing adoption of liquid biopsy and personalized medicine approaches, and heightened regulatory scrutiny regarding biospecimen quality and chain-of-custody integrity. In 2025 alone, global production of sample preservation solutions reached approximately 198 million units, with an average market price of around US$ 4 per unit. The VTM segment contributed an additional 52 million units to this figure, reflecting the essential role these products play in clinical and public health workflows.

What Exactly Is Sample Preservation Solution?

Sample preservation solution refers to a class of specialized reagent formulations integrated with stabilizers, inhibitors, buffering agents, and protective additives. These solutions are designed to maintain the structural integrity, biological activity, or chemical composition of diverse biological samples — including cells, tissues, nucleic acids, proteins, viruses, and body fluids — during collection, transport, and storage. By inhibiting the activity of degrading enzymes such as nucleases and proteases, preventing microbial contamination, and accommodating varied temperature conditions (ambient, refrigerated, or ultra-low-temperature), these solutions ensure that samples meet the stringent quality requirements of downstream applications ranging from clinical diagnosis and epidemiological surveillance to pharmaceutical R&D and biobanking.

Top-Tier Manufacturers and Supply Chain Dynamics

The sample preservation market is characterized by a mix of multinational life science conglomerates and specialized manufacturers focused on specific product categories or regional markets. At present, the major global manufacturers in the broader sample collection ecosystem include BD, Copan Group, Puritan Medical Products, and Thermo Fisher Scientific — entities that collectively accounted for approximately 70% of the global market share in recent years. Additional key players include Medical Wire (MWE), FL Medical, Deltalab, and Kangjian Medical, among others.

Within the VTM segment specifically, the competitive landscape mirrors this structure, with BD, Thermo Fisher, Copan Group, and Puritan Medical maintaining significant positions, joined by manufacturers such as MWE, Vircell, Deltalab, Hardy Diagnostics, Kangjian Medical, HiMedia Laboratories, and Huachenyang. This competitive ecosystem reflects a market in which established global players provide comprehensive end-to-end diagnostic workflows, while specialized manufacturers focus on high-volume production capabilities and flexible supply chain solutions that can rapidly respond to regional or global demand surges.

The Rising Prominence of China’s Manufacturing Ecosystem

China has emerged as a critical supply hub for the global sample preservation and diagnostic consumables industry. The country’s manufacturing capabilities, combined with an increasingly stringent domestic regulatory framework, have positioned Chinese manufacturers as essential partners for global IVD companies and healthcare systems seeking reliable, scalable, and compliant supply chains.

The Chinese regulatory framework, governed by the National Medical Products Administration (NMPA), imposes rigorous standards on sample preservation products. Manufacturers seeking NMPA Class I IVD filing for sample preservation solutions must demonstrate comprehensive compliance with stability testing requirements, storage condition validations, and quality control protocols. The NMPA mandates that stability studies conclusively demonstrate a product’s ability to meet its claimed specifications under defined storage conditions, with explicit documentation of temperature ranges — discouraging ambiguous descriptors like “room temperature” in favor of precise, validated parameters. Furthermore, manufacturers must evaluate the potential impact of different packaging configurations on product stability and ensure that all production occurs within quality-controlled environments.

For instance, a manufacturer holding a local NMPA Class I IVD filing for sample preservation solution — such as filing number Yue Shen Xie Bei 20230728 — demonstrates a high level of process control and regulatory adherence that aligns with international quality expectations. Such filings encompass detailed product specifications, including formulation transparency and extensive model specifications spanning volumes from 0.5 mL to 12 mL to accommodate diverse clinical and research applications.

The integration of Chinese manufacturers into the global supply chain is further evidenced by their attainment of multiple international certifications. Leading facilities now operate under ISO 13485 medical device quality management systems, maintain Class 100,000 GMP cleanroom production environments spanning approximately 15,000 m², and hold registrations across major regulatory jurisdictions, including EU CE marking, US FDA registration and 510(k) clearance, and Australian TGA approval. These credentials reflect a manufacturing ecosystem that has matured significantly, enabling Chinese suppliers to serve as reliable OEM and private-label partners for global diagnostic enterprises.

The Shift Toward “System-Based” Solutions (Swab + Media + Tube)

A defining trend in the sample preservation market is the industry-wide pivot from standalone reagent sales to integrated “system-based” solutions. The modern diagnostic workflow demands that the entire sampling ecosystem — the swab, the transport medium, and the collection tube — function as a cohesive, validated unit.

This shift is driven by a fundamental scientific reality: the performance of the preservation solution cannot be decoupled from the swab used to collect the specimen. Flocked swabs, which utilize a proprietary manufacturing process to create a uniform, brush-like nylon fiber surface, offer distinct advantages in sample collection and release. When paired with a custom-formulated preservation solution, flocked swabs can achieve sample elution rates exceeding 90%, maximizing the yield of target analytes for downstream detection. Conversely, traditional spun fiber swabs often entrap a significant portion of the collected sample, reducing the effective concentration of virus, bacteria, or nucleic acids available for analysis.

The downstream compatibility of the entire system is equally critical. Formulations that rely on guanidine thiocyanate for viral inactivation and nucleic acid stabilization — a widely adopted approach in inactivated VTM products — must be validated to ensure the absence of PCR inhibitors that could compromise assay sensitivity. Leading manufacturers now invest significantly in validating their complete collection systems across a spectrum of commercially available diagnostic platforms, including RT-PCR, isothermal amplification assays, and next-generation sequencing (NGS) workflows.

This “one partner, one system” approach offers end-users several advantages: reduced validation burden, streamlined procurement and inventory management, and — most importantly — enhanced confidence in the reliability of diagnostic results, particularly in high-stakes clinical and public health settings where sample integrity directly impacts patient care and epidemiological decision-making.

Future Outlook: Personalized Medicine and Liquid Biopsy

Looking beyond the immediate horizon, the sample preservation market is poised to benefit from transformative developments in personalized medicine and liquid biopsy technologies. The increasing utilization of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other cell-free nucleic acids as minimally invasive biomarkers for cancer detection and monitoring has created a specialized niche for preservation solutions capable of stabilizing these fragile analytes during transport from collection sites to centralized testing laboratories.

The non-invasive nucleic acid preservation reagents market is expected to grow from approximately US$ 1.68 billion in 2025 to US$ 3.06 billion by 2031, representing a CAGR of 10.5%. Similarly, the oral sample preservation reagent segment, which serves applications ranging from genetic testing to microbiome research, is projected to expand from US$ 963 million in 2024 to US$ 1.60 billion by 2031, advancing at a CAGR of 7.6%.

These specialized applications demand preservation formulations with distinct performance characteristics: the ability to stabilize cell-free DNA at ambient temperatures for extended periods, protection of fragile RNA species from rapid degradation, and compatibility with the ultra-sensitive detection chemistries employed in next-generation sequencing and digital PCR workflows. Manufacturers with robust R&D capabilities and flexible formulation expertise are well-positioned to capture share in these high-growth segments, particularly as liquid biopsy transitions from specialized oncology applications toward broader use in prenatal testing, transplant rejection monitoring, and infectious disease management.

Conclusion

The sample preservation solution market in 2026 represents a mature yet dynamic segment of the global diagnostics industry, characterized by steady growth, evolving competitive dynamics, and increasing regulatory sophistication. As diagnostic testing continues its expansion into decentralized settings and personalized medicine applications, the fundamental importance of sample integrity — the cornerstone upon which all downstream analyses rest — will only intensify. The manufacturers best positioned to thrive in this landscape will be those that combine rigorous regulatory compliance with manufacturing scalability and a commitment to validated, end-to-end system performance.